CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
C21drug
Likely dose
C21 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04533022
NCT04533022Phase 2Completed
CompareCT.gov

A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects With Idiopathic Pulmonary Fibrosis

Vicore Pharma AB·interventional·Posted Aug 31, 2020·Updated May 23, 2025

In Brief

A Phase 2 clinical trial evaluating C21 for Idiopathic Pulmonary Fibrosis. Completed, enrolled 52 participants across 21 sites in 4 countries.

Detailed Summary

This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety, efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesIndia, Russia, Ukraine, United Kingdom
CollaboratorsOrphan Reach Ltd.

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedAug 31, 2020
Enrollment StartNov 13, 2020
Primary CompletionMar 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 5.8 years ago

Interventions

C21drug

C21 100 mg BID (twice daily)